NasdaqGM:OCULPharmaceuticals
Ocular Therapeutix (OCUL) Heavy Losses Challenge Bullish Growth Narratives In Q1 2026 Earnings
Ocular Therapeutix (OCUL) opened 2026 with Q1 numbers that keep attention squarely on growth versus profitability, with trailing twelve month revenue at US$52 million and a loss of US$266 million translating into a Basic EPS of US$1.42 loss. Over the past six reported quarters, quarterly revenue has ranged from US$10.7 million to US$17.1 million while quarterly Basic EPS moved between US$0.22 and US$0.39 loss, underscoring a business that is building its top line but still carrying heavy...